Mer­ck touts new da­ta for Keytru­da com­bos in NSCLC at North Amer­i­can con­fer­ence

Mer­ck marched out new da­ta from two stud­ies on Fri­day to back king Keytru­da — the drug that made the Big Phar­ma $11.1 bil­lion last year — in ad­vanced non-small cell lung can­cer (NSCLC).

At the IASLC 2020 North Amer­i­ca Con­fer­ence on Lung Can­cer, Mer­ck read out long-term da­ta from Co­hort G of its Keynote-021 study, which as­sessed Keytru­da in com­bi­na­tion with chemother­a­py. It al­so tout­ed re­sults from a Phase I/II study test­ing Keytru­da and qua­von­limab, its an­ti-CT­LA-4 ther­a­py, as a first-line ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.